Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index; 64 of the 83 sources its claims cite were checked for support.

Research progress on HIV-1 structural proteins and antiviral therapies

Open access
Wang, Huihan, Yuan, Jinsong, Wang, Hong · 2026 · Frontiers in Immunology

Abstract

Human Immunodeficiency Virus (HIV), including HIV-1 and HIV-2, is a retrovirus that causes Acquired Immunodeficiency Syndrome (AIDS). HIV primarily targets the human immune system, especially CD4 + T lymphocytes, leading to progressive immune system dysfunction and rendering patients susceptible to severe opportunistic infections and malignancies. HIV-1 accounts for the majority of global HIV infections, and most structural, mechanistic, and therapeutic studies have been conducted in HIV-1 systems. The structural proteins Gag, Pol, and Env of HIV-1 play a pivotal role in the viral life cycle, making their functional mechanisms and inhibitor development key to advancing anti-AIDS drug research. This article provides a narrative review of recent advances in antiviral drug development targeting these proteins and discusses future design strategies. It offers critical insights for accelerating next-generation anti-HIV drug development and advancing global AIDS control efforts.

Overview

CoChat Summary

## TL;DR

This is a narrative review of HIV-1 structural proteins Gag, Pol, and Env, emphasizing how their functions make them key targets for antiviral drug development. It also reviews current therapies and future cure strategies, especially long-acting drugs, latency-reversal/silencing approaches, and gene-based interventions.

## Key findings

  • Gag, Pol, and Env are presented as indispensable for the HIV-1 replication cycle: Gag drives assembly and budding, Pol provides protease/reverse transcriptase/integrase functions, and Env mediates cell entry via CD4 and CCR5/CXCR4 interactions.
  • The review notes specific inhibitor progress: lenacapavir received FDA approval and allows subcutaneous dosing every 6 months; ibalizumab was FDA-approved in March 2018 for multidrug-resistant HIV-1; fostemsavir was approved in 2020 for heavily treatment-experienced adults with multidrug-resistant HIV-1.
  • For reverse transcriptase inhibitors, the paper states that 8 NRTIs and 6 NNRTIs have been clinically approved; it also names common resistance pathways, including M184V/I, K65R, and NNRTI-associated K103N, Y181C, E138K, K101E, and L100I.
  • The paper highlights long-acting regimen data: cabotegravir plus rilpivirine showed durable efficacy through 96 and 152 weeks in ATLAS-2M, and lenacapavir showed sustained antiviral activity in heavily treatment-experienced individuals with multidrug-resistant HIV-1 when combined with an optimized background regimen.

## Methods

  • Narrative review of recent literature on HIV-1 structural proteins and antiviral therapies, with a focus on HIV-1 rather than HIV-2.
  • No original sample, cohort, or experimental dataset is reported; the paper synthesizes published structural, mechanistic, clinical, and drug-development findings.
  • The analysis is qualitative and thematic, organizing evidence by protein target (Gag, Pol, Env), inhibitor class, clinical use, resistance, and future therapeutic directions.

## Limitations

  • The paper itself states it is a narrative review, so it does not present a systematic search protocol, meta-analysis, or new primary data; this limits the strength of any conclusions drawn from the paper itself.
  • It explicitly notes that clinical evidence for some HIV-2 applications is limited, including ibalizumab and maraviroc in HIV-2 settings.
  • Evident from the text: many claims about inhibitors, resistance, and future strategies are summarizations of prior studies rather than directly tested within this paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fimmu.2026.1805597

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Gag, Gag-Pol and Env polyprotein processing. (A) Proteolytic processing starts at the SP1–NC junction at the RQA|NFLG cleavage site, then proceeds to the MA–CA and SP2–p6 junctions at SQNY|PIV and PGNF|LQS, respectively. Subsequently, the spacer peptides SP1 and SP2 are trimmed from CA and NC at ARVL|AEA and RQAN|FLG. (B) The HIV-1 Gag–Pol polyprotein is generated by a programed −1 ribosomal frameshift at the NC/SP1 junction, placing the p6 region into an alternative reading frame to form the transframe domain (TF/p6*) upstream of Pol. Maturation is initiated by auto-processing at the TF|PR site (SFNF|PQIT), catalyzed by the weakly active protease precursor. This cleavage separates the N-terminal Gag-derived segment (MA–CA–SP1–NC–SP2–TF) from the Pol enzymes (PR–RT–RNase H–IN), releasing PR to drive subsequent ordered processing. (C) The Env protein is initially synthesized as a precursor, gp160 (a glycoprotein with an apparent molecular weight of 160 kDa), which undergoes processing by Furin. Subsequently, gp160 is cleaved by a cellular furin-like protease into two subunits: the receptor-binding subunit gp120 and the fusion subunit gp41.
Figure 1 Gag, Gag-Pol and Env polyprotein processing. (A) Proteolytic processing starts at the SP1–NC junction at the RQA|NFLG cleavage site, then proceeds to the MA–CA and SP2–p6 junctions at SQNY|PIV and PGNF|LQS, respectively. Subsequently, the spacer peptides SP1 and SP2 are trimmed from CA and NC at ARVL|AEA and RQAN|FLG. (B) The HIV-1 Gag–Pol polyprotein is generated by a programed −1 ribosomal frameshift at the NC/SP1 junction, placing the p6 region into an alternative reading frame to form the transframe domain (TF/p6*) upstream of Pol. Maturation is initiated by auto-processing at the TF|PR site (SFNF|PQIT), catalyzed by the weakly active protease precursor. This cleavage separates the N-terminal Gag-derived segment (MA–CA–SP1–NC–SP2–TF) from the Pol enzymes (PR–RT–RNase H–IN), releasing PR to drive subsequent ordered processing. (C) The Env protein is initially synthesized as a precursor, gp160 (a glycoprotein with an apparent molecular weight of 160 kDa), which undergoes processing by Furin. Subsequently, gp160 is cleaved by a cellular furin-like protease into two subunits: the receptor-binding subunit gp120 and the fusion subunit gp41.CC BY · PubMed Central
Figure 2 HIV-1 replication cycle and the indication of drugs target structural proteins. Upon entering the target cell, reverse transcriptase (RT) transcribes genomic RNA into a reverse transcription complex (RTC). Through IN processing of viral DNA ends, a proviral integration complex (PIC) is generated, which can integrate endogenous DNA prepared by reverse transcription into the DNA. After nuclear entry, the provirus serves as a template for transcription, producing mRNAs that are used to translate viral proteins and assemble with viral proteins into the viral genome. Subsequently, budding occurs, releasing mature HIV-1 virus particles.
Figure 2 HIV-1 replication cycle and the indication of drugs target structural proteins. Upon entering the target cell, reverse transcriptase (RT) transcribes genomic RNA into a reverse transcription complex (RTC). Through IN processing of viral DNA ends, a proviral integration complex (PIC) is generated, which can integrate endogenous DNA prepared by reverse transcription into the DNA. After nuclear entry, the provirus serves as a template for transcription, producing mRNAs that are used to translate viral proteins and assemble with viral proteins into the viral genome. Subsequently, budding occurs, releasing mature HIV-1 virus particles.CC BY · PubMed Central

Verification

Claims the paper makes

42 Valid · 2 Not valid · 3 Not checked · 5 Own results and interpretations

17 more claims · 13 with their cited sources checked

Create a free account to see all 52 claims and to verify the 11 references still open.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 139 references

Metadata

Authors
Wang, H., Yuan, J., & Wang, H.
Affiliations
First Hospital of Jilin University (CN)
Corresponding author
Wang, Hong
Venue
Frontiers in Immunology
Published
2026-06-03
Volume
17
Pages
1805597-1805597
ISSN
1664-3224 (ISSN-L)
OpenAlex
W7163380950
Cited by
2
References
139
Citations by year
2026: 2
FWCI
2.78
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords
HIV-1, structural proteins, Gag, pol, Env, antiviral drug discovery, HIV-1 life cycle, CD4+ T cells, AIDS, HIV-2, drug design strategies
MeSH terms
Animals, Humans, HIV-1, HIV Infections, Anti-HIV Agents, gag Gene Products, Human Immunodeficiency Virus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Research progress on HIV-1 structural proteins and antiviral therapies. https://app.cochat.ai/papers/10.3389/fimmu.2026.1805597
The paper
Wang, H., Yuan, J., & Wang, H. (2026). Research progress on HIV-1 structural proteins and antiviral therapies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1805597

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.